More Post from the Author
- Coastal Mississippi Elevates Ari Covacevich to Lead Sales & Business Development
- Adventure Isn't Just For the Backcountry - Storyteller Overland Brings Badassery To The Big Apple
- Cunard reveals first phase of 2026 Event Voyages program
- Unifi expands UK Operations with Ground Handling and Security Contracts at London Oxford Airport
- United Airlines Reports Best First-Quarter Financial Performance in Five Years Despite Challenging Macroeconomic Environment
Bioretec Ltd's Annual Report 2024 published
Bioretec Ltd Press Release 14 March 2025 at 7:00 p.m. EET
TAMPERE, Finland, March 14, 2025 /PRNewswire/ -- Bioretec Ltd has today published its 2024 Annual Report. The Annual Report is attached to this release and also available in Finnish and English on the company's website at https://investors.bioretec.com/en/reports_and_presentations. Bioretec's previously published financial statements for 2024 are also available on the company's website.
Further enquiries
Alan Donze, CEO,+1 619 977 5285
Johanna Salko, CFO, +358 40 754 8172
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Bioretec in brief
Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in thebiological interfaceof active implantsto enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
Bioretec isdevelopingthe new RemeOsproduct linebased on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing onvalue for patients through efficient healthcare. The first RemeOs product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.
Better healing - Better life. www.bioretec.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bioretec/r/bioretec-ltd-s-annual-report-2024-published,c4119341
The following files are available for download:
https://mb.cision.com/Public/20509/4119341/9b2d6753d360aa72.pdf | Annual Report 2024 Bioretec |

More Post from the Author
- Coastal Mississippi Elevates Ari Covacevich to Lead Sales & Business Development
- Adventure Isn't Just For the Backcountry - Storyteller Overland Brings Badassery To The Big Apple
- Cunard reveals first phase of 2026 Event Voyages program
- Unifi expands UK Operations with Ground Handling and Security Contracts at London Oxford Airport
- United Airlines Reports Best First-Quarter Financial Performance in Five Years Despite Challenging Macroeconomic Environment